tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ENTA Stock Latest News

Enanta’s New RSV Trial in Infants: What Investors Should Watch in ENTA
Company AnnouncementsEnanta’s New RSV Trial in Infants: What Investors Should Watch in ENTA
5d ago
ENTA
Enanta Shareholders Approve Board Elections and Equity Plan
PremiumCompany Announcements
Enanta Shareholders Approve Board Elections and Equity Plan
11d ago
8K
ENTA
Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity
PremiumRatings
Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity
1M ago
ENTA
Enanta files $150M mixed securities shelf
PremiumThe Fly
Enanta files $150M mixed securities shelf
1M ago
ENTA
Enanta reports Q1 EPS (42c), consensus (88c)
PremiumThe Fly
Enanta reports Q1 EPS (42c), consensus (88c)
1M ago
ENTA
Enanta Pharmaceuticals (ENTA) Q1 Earnings Cheat Sheet
PremiumPre-EarningsEnanta Pharmaceuticals (ENTA) Q1 Earnings Cheat Sheet
1M ago
ENTA
Enanta Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating
Premium
Ratings
Enanta Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating
4M ago
ENTA
Enanta Pharmaceuticals Reports Progress in Drug Development
Premium
Company Announcements
Enanta Pharmaceuticals Reports Progress in Drug Development
4M ago
ENTA
Enanta reports Q4 EPS (87c), consensus ($1.01)
PremiumThe Fly
Enanta reports Q4 EPS (87c), consensus ($1.01)
4M ago
ENTA
Is ENTA a Buy, Before Earnings?
PremiumPre-Earnings
Is ENTA a Buy, Before Earnings?
4M ago
ENTA
Buy Rating for Enanta Pharmaceuticals Driven by Promising RSV Drug Pipeline and Market Potential
PremiumRatings
Buy Rating for Enanta Pharmaceuticals Driven by Promising RSV Drug Pipeline and Market Potential
4M ago
ENTA
Enanta initiated with an Overweight at JPMorgan
PremiumThe Fly
Enanta initiated with an Overweight at JPMorgan
4M ago
ENTA
Enanta Pharmaceuticals Announces Public Stock Offering
PremiumCompany AnnouncementsEnanta Pharmaceuticals Announces Public Stock Offering
6M ago
8K
ENTA
Enanta upgraded to Buy from Hold at Jefferies
Premium
The Fly
Enanta upgraded to Buy from Hold at Jefferies
6M ago
ENTA
Enanta upgraded to Buy at Jefferies on higher confidence in RSV antiviral
Premium
The Fly
Enanta upgraded to Buy at Jefferies on higher confidence in RSV antiviral
6M ago
ENTA
Enanta 6.5M share Spot Secondary priced at $10.00
PremiumThe Fly
Enanta 6.5M share Spot Secondary priced at $10.00
6M ago
ENTA
Closing Bell Movers: Nike rallies 4% after earnings beat and guidance
PremiumThe Fly
Closing Bell Movers: Nike rallies 4% after earnings beat and guidance
6M ago
AIR
COP
Enanta $50M Spot Secondary; price range $10.00-$10.50
PremiumThe Fly
Enanta $50M Spot Secondary; price range $10.00-$10.50
6M ago
ENTA
Enanta announces $50M common stock offering
PremiumThe Fly
Enanta announces $50M common stock offering
6M ago
ENTA
Promising Phase 2b Trial Results for Enanta Pharmaceuticals’ Zelicapavir Boost Buy Rating and $20 Price Target
PremiumRatingsPromising Phase 2b Trial Results for Enanta Pharmaceuticals’ Zelicapavir Boost Buy Rating and $20 Price Target
6M ago
ENTA
Enanta Pharmaceuticals Announces Positive Phase 2b Results
Premium
Company Announcements
Enanta Pharmaceuticals Announces Positive Phase 2b Results
6M ago
8K
ENTA
Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results
Premium
Company Announcements
Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results
6M ago
8K
ENTA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >